Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Nasal congestion10 mg 4 hourly for up to 7 days. Max: 60 mg/day. IV Hypotensive states As 0.1% soln: Initial: 100-500 mcg/dose via IV inj every 15 minutes. Severe: 180 mcg/minute via infusion, adjusted to 30-60 mcg/minute according to response. Paroxysmal supraventricular tachycardia Initial: Up to 500 mcg, increased in increments of 100-200 mcg up to 1 mg. SC/IM Hypotensive states As 1% soln: Initial: 2-5 mg, with further doses up to 1-10 mg after at least 15 minutes. Ophthalmic Production of mydriasis As 2.5 or 10% eye drop solution: Instill 1 drop to each eye prior to procedure. If necessary, repeat dose once only after at least 1 hour. Max: 3 drops/eye. Rectal Haemorrhoids As 0.25% cream/gel/ointment: Apply to clean, dry area up to 4 times/day. As supp: Insert 1 supp up to 4 times/day. Max: 2 mg/day. Nasal Nasal congestion As 0.25-1% solution: Instill 2-3 drops/sprays in each nostril 4 hourly as needed.
Should be taken with food.
Severe hypertension, ventricular tachycardia, severe hyperthyroidism. Ophthalmic (10% solution): Close-angle glaucoma. Children and elderly. Cold preparations should not be used in children <2 years. Concomitant or within 14 days of MAOI use (oral).
Special Precautions
Patient with CV disease (e.g. ischaemic heart disease, pre-existing bradycardia, partial heart block, severe coronary artery disease, heart failure, cardiogenic shock), diabetes mellitus, asthma, arteriosclerosis, aneurysm, hypertension, narrow-angle glaucoma. Renal impairment (IV). Children. Elderly. Pregnancy (especially those with history of pre-eclampsia) and lactation. Patient Counselling Eye drops may cause temporary blurring of vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure.
Adverse Reactions
Significant: Reflex bradycardia, extravasation (IV); rebound miosis (ophthalmic); Cardiac disorders: Arrhythmia, ischemia, extrasystoles, palpitation, tachycardia. Eye disorders: Eye pain, irritation, stinging or burning sensation, blurred vision, photophobia, mydriasis, vitreous opacity (transient). Gastrointestinal disorders: Nausea, vomiting. Nervous system disorders: Headache, paresthesia,tremor, weakness. Psychiatric disorders: Anxiety, agitation, insomnia, nervousness, excitability. Renal and urinary disorders: Urinary retention (in males). Respiratory, thoracic and mediastinal disorders:Skin and subcutaneous tissue disorders: Blanching of skin, pallor, piloerection. Vascular disorders: Hypertension, hypertensive crisis.
Potentially Fatal: Cerebral haemorrhage, ventricular arrhythmia, myocardial infarction.
Drug Interactions
Concomitant use with adrenergic blocking agents (e.g. phentolamine), phenothiazine drugs (e.g. chlorpromazine) and amiodarone may cause antagonistic effects. May potentiate pressor effects of oxytocic drugs and CV depressant effects of inhalational anaesthetics (e.g. cyclopropane, halothane). May increase risk of arrythmias with cardiac glycosides and quinidine. May enhance the effects of anticholinergic drugs (e.g. TCAs).
ATC Classification
R01AB01 - phenylephrine ; Belongs to the class of topical sympathomimetic combination preparations, excluding corticosteroids. Used as nasal decongestants.
C01CA06 - phenylephrine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
S01GA05 - phenylephrine ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
S01FB01 - phenylephrine ; Belongs to the class of sympathomimetics used as mydriatics and cycloplegics.
R01BA03 - phenylephrine ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
R01AA04 - phenylephrine ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
Disclaimer: This information is independently developed by CIMS based on phenylephrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in